http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Amgen Submits Supplemental New Drug Application For Kyprolis® (Carfilzomib) In Relapsed Multiple Myeloma
-
European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol
-
Amgen Announces Positive BLINCYTO® (blinatumomab) Phase 2 Study Results In Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
-
Amgen Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic Migraine
-
Results From Phase 3 Trial Show Vectibix® (Panitumumab) Improves Overall Survival In Chemorefractory Wild-Type KRAS Metastatic Colorectal Cancer Versus Best Supportive Care
-
Amgen To Discuss Details Of Repatha™ (Evolocumab) Biologics License Application For The Treatment Of High Cholesterol
-
Amgen To Present At The Goldman Sachs Global Healthcare Conference
-
Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease
-
Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab
-
Amgen Presents Phase 3 Data At ASCO Showing Prolia® (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Patients Receiving Aromatase Inhibitors
-
Amgen Initiates Phase 3 Study Evaluating Once-Weekly Kyprolis® (carfilzomib) in Patients With Relapsed And Refractory Multiple Myeloma
-
Amgen And Merck Announce Expansion Of Collaboration To Support Studies Of Talimogene Laherparepvec In Combination With KEYTRUDA® (Pembrolizumab) In Patients With Head And Neck Cancer
-
Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease
-
Amgen Launches Program To Further Advance Basic Biology Research
-
Amgen To Present At The Jefferies 2015 Global Healthcare Conference
-
Amgen To Advance Understanding Of The Treatment Of Blood Cancers At 20th Congress of European Hematology Association (EHA)
-
Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma
-
Amgen to terminate participation in co-development and commercialization of brodalumab
-
Amgen Receives Positive CHMP Opinion For Use Of Repatha™ (Evolocumab) For The Treatment Of High Cholesterol
-
Amgen Appoints Jonathan P. Graham Senior Vice President, General Counsel And Secretary
-
Amgen Presents First Phase 2 Data For AMG 334 In The Prevention Of Episodic Migraine
-
Amgen Announces Voting Results of Annual Meeting of Stockholders
-
Amgen Data At ASCO 2015 Highlight Oncology Pipeline And Portfolio
-
Amgen's Breakaway From Cancer® Announces Winners Of Its Nationwide Search For Champions In The Fight Against Cancer
-
Amgen To Present AMG 334 Data At 17th Congress of the International Headache Society
-
Amgen To Present At The Deutsche Bank 40th Annual Healthcare Conference
-
Amgen Announces FDA Advisory Committee Meeting To Review Repatha™ (Evolocumab) As A Treatment For High Cholesterol
-
Amgen To Discuss Details Of The Biologics License Application For Talimogene Laherparepvec For Patients With Metastatic Melanoma
-
Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48
-
BeyondTrust Appoints Former Northrop Grumman Chairman and CEO Dr. Ronald D. Sugar to Board of Directors
-
Amgen Announces Webcast Of 2015 First Quarter Financial Results
-
FDA Approves Corlanor® (ivabradine) To Reduce The Risk Of Hospitalization For Worsening Heart Failure In Patients With Chronic Heart Failure
-
European Commission Approves Amgen's Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer
-
Amgen To Present At The Goldman Sachs Key Debates In Biosimilars Conference
-
FDA Grants Amgen Priority Review for Kyprolis® (Carfilzomib) Supplemental New Drug Application for the Treatment of Relapsed Multiple Myeloma
-
Cancer Survivor Joan Lunden Named 2015 Honorary Breakaway From Cancer® Champion And Joins Nationwide Search For Ten Champions In The Fight Against Cancer
-
Amgen To Webcast Investor Call At the 73rd Annual Meeting of the American Academy of Dermatology
-
Amgen Submits Application For Investigational LDL Cholesterol-Lowering Medication Repatha™ (evolocumab) In Japan
-
Amgen To Present 10 Abstracts From Its Dermatology Portfolio At The 73rd Annual Meeting Of The American Academy Of Dermatology
-
Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha™ (evolocumab) In The New England Journal of Medicine
-
New Detailed Data From Phase 3 Study Show Amgen's Repatha™ (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular R
-
Pre-Open Stock Movers 10/28: (RCPT) (TRNX) (VDSI) (MSG) Higher; (TWTR) (AMKR) (CVLT) Lower (more...)
-
After-Hours Stock Movers 10/27: (TRNX) (RCPT) (SANM) Higher; (AKMR) (TWTR) (KSS) Lower (more...)
-
UPDATE: Gilead Sciences (GILD) Hits Session Lows
-
Top 10 Trending Stocks for 07/30: Twitter (TWTR), Amgen (AMGN), Regeneron (REGN), and More...
-
Pre-Open Stock Movers 7/30: (GFIG) (TWTR) (NQ) Higher; (NTRI) (BWLD) (DWA) Lower (more...)
-
After-Hours Stock Movers 7/29: (TWTR) (ZLTQ) (X) Higher; (NTRI) (BWLD) (DWA) Lower (more...)
-
Market Wrap: Home Prices Gain at Slower Pace; Twitter Soars in Q2; Ford Opts for Apple
-
Trading Radar for 07/29: Pfizer (PFE), Marriott (MAR), UPS (UPS), Anadarko (APC), Ballard Power (BLDP) Report

